Please upgrade your browser.
Eisai announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.
The Kidney Cancer Association announces another Young Investigator Award (YIA) made collaboratively with Conquer Cancer Foundation (ASCO). The Award is a research grant that supports promising investigators and encourages quality research in clinical oncology, providing funding during a physician’s pivotal career transition from a fellowship program to a faculty appointment.
But when inflammation is chronic, lasting for months or even years due to injury or disease, it can become a perfect environment for many types of cancer cells to develop and thrive.
Roughly 2-3 percent of all people suffering from cancer have kidney cancer. The most common form of this disease is called clear cell renal cell carcinoma (ccRCC). In roughly half of all patients with this disease, the tumor develops metastases and generally cannot be cured.
Women who eat more tomatoes or other lycopene-containing fruits and vegetables may have a lower risk of developing kidney cancer, a study suggests.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco ("UCSF") to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma ("RCC").
“We have never seen anything like this in most human solid tumors,” Allegheny Health Network Oncologist Dr. Gene Finley said.
The companies are taking advantage of frightened cancer patients and their loved ones, said consumer safety officer Nicole Kornspan.
Researchers at the Mayo Clinic found surgery for patients with late-stage kidney cancer may more than double their life expectancy.
|NeonCRM by Neon One|